Cart

PharmaCyte Biotech Inc

Profile:Symbol: PMCB
HQ: Laguna Hills CA
Incorporated: 1996 as a neutraceutical firm. In 2013, restructured as a biopharma. In 2015 it changed its name from Nuvilex, Inc. to PharmaCyte Biotech.

Focus: StrongPharmaCyte has licensed a medical technology called Cell in a Box, and is using it in early stage clinical trials to improve existing treatments for cancer and diabetes, by better controlling the place and time of the treatment’s release.

It is also developing new treatments for cancer and diabetes to deliver with this technology, some of these derived from cannabis (for cancer). The company currently reports little about these new treatments, but a lot about the Cell in a Box delivery technology.

Cell in a Box technology could eventually itself be a revenue-producing technology, with or without a new treatment. Cell in a Box potentially allows for more specific targeting of medical treatments such as chemotherapy to where the treatment is needed in the body, thus reducing the side effects in other parts of the body.

Size:Market Cap: $54 mil
Enterprise Value: $53 mil
# of employees: 4

Markets: StrongIf they develop a marketable product, the initial market will be US, Europe.

Operations:WeakProduction: PharmaCyte does not yet produce a productDistribution: No distribution yet (no sales or product yet)

Integration/Diversification:Vertically integrated: No
Horizontally diversified: No, they currently are focused on one product

Risks:HighThe risks of investing in any cannabis company are currently high given the newness of the market. The risks of investing in this company are very high, since it does not yet have a product or any revenue or income.

Recommendation: WeakIn terms of investing, this company currently has a few positive points, but more than a few negative ones.

Get the Q1, ’19 Cannin Report ($99)

Includes the latest market & industry update, 12 technical fundamental analyses, latest regulations by state, new medical research and more!

Previous ProjectOWC Pharma

Next ProjectPivot Pharmaceuticals

Risk of Prosecution for Marijuana-Related Companies. If you are considering investing in a company that is connected to the marijuana industry, be aware that marijuana-related companies may be at risk of federal, and perhaps state, criminal prosecution. The Department of Treasury recently issued guidance noting: “[T]he Controlled Substances Act (“CSA”) makes it illegal under federal law to manufacture, distribute, or dispense marijuana. Many states impose and enforce similar prohibitions. Notwithstanding the federal ban, as of the date of this guidance, 20 states and the District of Columbia have legalized certain marijuana-related activity.”